A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate

Annals of the Rheumatic Diseases

Volumn 72, Issue 9, 2013, Pages 1453-1460

  Genovese, Mark C ^a   Lee, Eric ^b   Satterwhite, Julie ^c   Veenhuizen, Melissa ^c   Disch, Damon ^c   Berclaz, Pierre Yves ^c   Myers, Stephen ^c   Sides, Gregory ^c   Benichou, Olivier ^c  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b Inland Rheumatology and Osteoporosis Medical Group   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; METHOTREXATE; PLACEBO; RHEUMATOID FACTOR; TABALUMAB;

ADULT; AMERICAN COLLEGE OF RHEUMATOLOGY CRITERIA; ANTIBODY TITER; ARTICLE; BAYES THEOREM; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DAS28; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION ROUTE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEMIPLEGIA; HUMAN; IMMUNOGENICITY; IMMUNOSTIMULATION; INFECTION; INFLUENZA A (H1N1); MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; STATISTICAL MODEL; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION;

AUTOIMMUNE DISEASES; B CELLS; RHEUMATOID ARTHRITIS; TNF-ALPHA;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG RESISTANCE; FEMALE; HEALTH STATUS; HUMANS; INJECTIONS, SUBCUTANEOUS; JOINTS; MALE; METHOTREXATE; MIDDLE AGED; PILOT PROJECTS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84881480714     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-202864     Document Type: Article

References (25)

1. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 2002;46:328-46.
2. Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet 2009;373:659-72.
3. Rindfleisch JA, Muller D. Diagnosis and management of rheumatoid arthritis. Am Fam Physician 2005;72:1037-47. (Pubitemid 43093259)
4. Schneider P, Mackay F, Steiner V, et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999;189:1747-56. (Pubitemid 29272691)
5. Bosello S, Youinou P, Daridon C, et al. Concentrations of BAFF correlate with autoantibody levels, clinical disease activity, and response to treatment in early rheumatoid arthritis. J Rheumatol 2008;35:1256-64. (Pubitemid 352000768)
6. Ohata J, Zvaifler NJ, Nishio M, et al. Fibroblast-like synoviocytes of mesenchymal origin express functional B cell-activating factor of the TNF family in response to proinflammatory cytokines. J Immunol 2005;174:864-70. (Pubitemid 40094281)
7. Melchers F. Actions of BAFF in B cell maturation and its effects on the development of autoimmune disease [abstract]. Ann Rheum Dis 2003;62(Suppl 2): ii25-7.
8. Mackay F, Schneider P. Cracking the BAFF code. Nat Rev Immunol 2009;9:491-502.
9. Moura RA, Weinmann P, Pereira PA, et al. Alterations on peripheral blood B-cell subpopulations in very early arthritis patients. Rheumatology (Oxford) 2010;49:1082-92.
10. Silverman GJ, Carson DA. Roles of B cells in rheumatoid arthritis [abstract]. Arthritis Res Ther 2003;5(Suppl 4):S1-6. (Pubitemid 38239909)
11. Kikly K, Manetta J, Smith H, et al. Characterization of LY2127399, A neutralizing antibody for BAFF [abstract]. Arthritis Rheum 2009;60(Suppl 10):693.
12. Genovese MC, Mociran E, Biagini M, et al. Phase 2 study of safety and efficacy of a novel anti-BAFF monoclonal antibody, in patients with RA treated with methotrexate (MTX). [abstract]. Arthritis Rheum 2009;60(Suppl 10):1923.
13. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24. (Pubitemid 18091653)
14. Berry DA. Bayesian clinical trials. Nat Rev Drug Discov 2006;5:27-36.
15. Bourdage JS, Cook CA, Farrington DL, et al. An Affinity Capture Elution (ACE) assay for detection of anti-drug antibody to monoclonal antibody therapeutics in the presence of high levels of drug. J Immunol Methods 2007;327:10-17. (Pubitemid 47444307)
16. Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 2001;40:205-11.
17. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806. (Pubitemid 44497758)
18. McKay J, Chwalinska-Sadowska H, Boling E, et al. Belimumab (BmAb), a fully human monoclonal antibody to B-lymphocyte stimulator (BLyS), combined with standard of care therapy reduces the signs and symptoms of rheumatoid arthritis in a heterogeneous subject population [abstract]. Arthritis Rheum 2005;52(Suppl 9):S710.
19. Genovese MC, Filipowicz-Sosnowska A, Merrill J, et al. Differential responsiveness of belimumab (BmAb) in combination with standard of care therapy in RF+, TNFa inhibitor and MTX partial responder subgroups with moderate-severe rheumatoid arthritis [abstract]. Arthritis Rheum 2005;52(Suppl 9):S1989.
20. Genovese MC, Kinnman N, de La Bourdonnave G, et al. Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a phase II, randomized, placebo-controlled, dose-finding trial. Arthritis Rheum 2011;63:1793-803.
21. van Vollenhoven RF, Kinnman N, Vincent E, et al. Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo-controlled trial. Arthritis Rheum 2011;63:1782-92.
22. Shaw M, Trapp R, Del Giudice J, et al. The effects of repeated doses of briobacept (Br3-Fc) in patients with rheumatoid arthritis [abstract]. Ann Rheum Dis 2008;67 (Suppl II):87.
23. Tak PP, Thurlings RM, Rossier C, et al. Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single-and repeated-dose study. Arthritis Rheum 2008;58:61-72.
24. Lilly discontinues one of three phase 3 rheumatoid arthritis registration studies for tabalumab-FLEX-M study did not meet efficacy expectations in an interim futility analysis; discontinuation not based on safety concerns. Eli Lilly and Company. 13 December 2012.
25. Lilly discontinues phase 3 rheumatoid arthritis program for tabalumab based on efficacy results-decision not based on safety concerns; phase 3 lupus program continues as planned. Eli Lilly and Company. 7 February 2013.